<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="334">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04374279</url>
  </required_header>
  <id_info>
    <org_study_id>COV2003</org_study_id>
    <secondary_id>IRB00249425</secondary_id>
    <nct_id>NCT04374279</nct_id>
  </id_info>
  <brief_title>Trial to Promote Recovery From COVID-19 With Endocrine Therapy</brief_title>
  <acronym>RECOVER</acronym>
  <official_title>A Phase II Trial to Promote Recovery From COVID-19 With Endocrine Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with COVID-19 requiring inpatient hospitalization will be randomized to treatment
      with standard of care or standard of care + bicalutamide. This will be a randomized,
      open-label study to determine if bicalutamide improves the rate of clinical improvement in
      patients with COVID-19.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2020</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomized 1:1 to bicalutamide with standard of care, or standard of care alone.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants who have clinical improvement at day 7 after randomization</measure>
    <time_frame>up to 7 days</time_frame>
    <description>Percentage of participants who are discharged from the hospital or if they have had at least a 2-point improvement on the World Health Organization (WHO) Ordinal Scale for Clinical Improvement. The WHO clinical improvement scale has a score range of 0-8 where, 0= uninfected, 1= ambulatory with no limitation of activities; 2= ambulatory with limitations to activities; 3= hospitalized, mild disease, with no oxygen therapy; 4= hospitalized, mild disease, with oxygen by mask or nasal prongs; 5= hospitalized, severe disease, with non-invasive ventilation or high-flow oxygen; 6= hospitalized, severe disease, with intubation and mechanical ventilation; 7= hospitalized, severe disease, with ventilation and additional organ support (pressors, dialysis, ECMO); 8= death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>28 days</time_frame>
    <description>Number of participants deceased for any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>up to 60 days</time_frame>
    <description>Number of calendar days in the hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients needing upgrade to the intermediate care unit (IMC)</measure>
    <time_frame>up to 60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of IMC stay</measure>
    <time_frame>up to 60 days</time_frame>
    <description>Number of calendar days in IMC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients needing upgrade to the intensive care unit (ICU)</measure>
    <time_frame>up to 60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ICU stay</measure>
    <time_frame>up to 60 days</time_frame>
    <description>Number of calendar days in ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants requiring mechanical ventilation</measure>
    <time_frame>up to 60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>up to 60 days</time_frame>
    <description>Number of calendar days requiring mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing adverse events</measure>
    <time_frame>up to 60 days</time_frame>
    <description>Number of participants who are COVID-19 positive, experiencing adverse events as defined by the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) version 5.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>COVID-19</condition>
  <condition>SARS-CoV 2</condition>
  <arm_group>
    <arm_group_label>Standard of care and bicalutamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Randomized participants receive bicalutamide 150mg oral for 7 days, plus standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care only</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Randomized participants receive standard of care only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bicalutamide 150 Mg Oral Tablet</intervention_name>
    <description>Bicalutamide 150 mg by mouth daily for 7 days</description>
    <arm_group_label>Standard of care and bicalutamide</arm_group_label>
    <other_name>Casodex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥18 years of age

          -  COVID-19 infection, confirmed by polymerase chain reaction (PCR) test &lt;=3 days from
             enrollment

          -  Require inpatient hospitalization due to COVID-19 with minimal respiratory symptoms

          -  Able to provide informed consent

        Exclusion Criteria:

          -  Unable to take oral medication

          -  Pregnant or breastfeeding

          -  On non-invasive positive pressure ventilation or mechanical ventilation at time of
             study entry

          -  Requiring ≥6L oxygen or respiratory rate ≥30

          -  Taking bicalutamide, any systemic hormonal therapy, or prophylactic treatment for
             COVID-19 within one month of study entry

          -  Known hypersensitivity to bicalutamide or its components.

          -  A past medical history of cirrhosis or AST/ALT/Alk phos/bilirubin &gt; 3x the upper limit
             of normal

          -  Patients with a clinical history of myocardial infarction or congestive heart failure
             within 6 months, or with prior echocardiogram showing ejection fraction &lt; 40%

          -  Patients currently on coumadin anticoagulants due to the potential for drug-drug
             interactions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine H Marshall, MD/MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Catherine H Marshall, MD/MPH</last_name>
    <phone>410-955-0231</phone>
    <email>chm@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aliya Lalji, MD</last_name>
    <phone>410-502-5101</phone>
    <email>alalji1@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Catherine H Marshall, MD/MPH</last_name>
      <phone>410-955-0231</phone>
      <email>chm@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Samuel Denmeade, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vasan Yegnasubramanian, MD/PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shawn Kwatra, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lindsey Hayes, MD/PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffrey Rothstein, MD/PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>May 4, 2020</study_first_submitted>
  <study_first_submitted_qc>May 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2020</study_first_posted>
  <last_update_submitted>October 1, 2020</last_update_submitted>
  <last_update_submitted_qc>October 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Coronavirus</keyword>
  <keyword>COVID</keyword>
  <keyword>SARS-COV-2</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bicalutamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

